JP2017514839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514839A5 JP2017514839A5 JP2016565403A JP2016565403A JP2017514839A5 JP 2017514839 A5 JP2017514839 A5 JP 2017514839A5 JP 2016565403 A JP2016565403 A JP 2016565403A JP 2016565403 A JP2016565403 A JP 2016565403A JP 2017514839 A5 JP2017514839 A5 JP 2017514839A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pyrrolo
- methyl
- pyrimidin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 125000004193 piperazinyl group Chemical group 0.000 claims 9
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- -1 2- (morpholin-4-yl) ethyl Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- CHBISLXEGUDRRV-SFHVURJKSA-N CCCC[C@H](C)NC1=NC(=NC2=C1N(C=C2)CC3=C(C=CC(=C3)CN4CCNCC4)OC)N Chemical compound CCCC[C@H](C)NC1=NC(=NC2=C1N(C=C2)CC3=C(C=CC(=C3)CN4CCNCC4)OC)N CHBISLXEGUDRRV-SFHVURJKSA-N 0.000 claims 2
- SBILKCCWZZAMEO-UHFFFAOYSA-N COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=C(C=C1)CN1CCNCC1 Chemical compound COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=C(C=C1)CN1CCNCC1 SBILKCCWZZAMEO-UHFFFAOYSA-N 0.000 claims 2
- LMXTZUAHGZBEKB-UHFFFAOYSA-N COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=CC(=C1)CN1CCNCC1 Chemical compound COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=CC(=C1)CN1CCNCC1 LMXTZUAHGZBEKB-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- QRJUJOQGEKSMAJ-UHFFFAOYSA-N NC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound NC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC QRJUJOQGEKSMAJ-UHFFFAOYSA-N 0.000 claims 2
- IIILSKLUXKONMT-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)N2CCOCC2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)N2CCOCC2)OC)NCCCCC IIILSKLUXKONMT-UHFFFAOYSA-N 0.000 claims 2
- GTZVTPGTXBZOIN-FQEVSTJZSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CN2CCNCC2)OC)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CN2CCNCC2)OC)N[C@H](CO)CCCC GTZVTPGTXBZOIN-FQEVSTJZSA-N 0.000 claims 2
- QLZDGWRAIFYJAV-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)OCC(=O)N2CCOCC2)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)OCC(=O)N2CCOCC2)NCCCCC QLZDGWRAIFYJAV-UHFFFAOYSA-N 0.000 claims 2
- KNMSPDSJHHYLOT-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)O)C=CC2OC)NCCCCC KNMSPDSJHHYLOT-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- QWJGXSAWJMJJNM-UHFFFAOYSA-N 2-(dimethylamino)ethyl 4-[[2-amino-4-(pentylamino)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-3-methoxybenzoate Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C(=O)OCCN(C)C)C=C2)OC)NCCCCC QWJGXSAWJMJJNM-UHFFFAOYSA-N 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- MYRNVYLFILMXIA-UHFFFAOYSA-N CCCCCNC1=NC(N)=NC2=C1N(CC(C=C(C=C1)OOC(C)=O)=C1OC)C=C2 Chemical compound CCCCCNC1=NC(N)=NC2=C1N(CC(C=C(C=C1)OOC(C)=O)=C1OC)C=C2 MYRNVYLFILMXIA-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- OWWMDXNTWDIJTR-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C(=O)OCCOCCN(C)C)C=C2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C(=O)OCCOCCN(C)C)C=C2)OC)NCCCCC OWWMDXNTWDIJTR-UHFFFAOYSA-N 0.000 claims 1
- ZXQMNLAFFOUHIX-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)N(C)C)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)N(C)C)OC)NCCCCC ZXQMNLAFFOUHIX-UHFFFAOYSA-N 0.000 claims 1
- CWZMIMVFFXBCGL-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)N(CCC)CCC)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)N(CCC)CCC)OC)NCCCCC CWZMIMVFFXBCGL-UHFFFAOYSA-N 0.000 claims 1
- ANQLBQCZOMUHDE-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)OCC2=CC=CC=C2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCC(=O)OCC2=CC=CC=C2)OC)NCCCCC ANQLBQCZOMUHDE-UHFFFAOYSA-N 0.000 claims 1
- MEQGHEXQNNTNNQ-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCCCN(C)C)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCCCN(C)C)OC)NCCCCC MEQGHEXQNNTNNQ-UHFFFAOYSA-N 0.000 claims 1
- URJBQKFMEUCALS-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCN2CCN(CC2)C)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCN2CCN(CC2)C)OC)NCCCCC URJBQKFMEUCALS-UHFFFAOYSA-N 0.000 claims 1
- LIHUPNDPYYFZRX-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCN2CCNCC2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCN2CCNCC2)OC)NCCCCC LIHUPNDPYYFZRX-UHFFFAOYSA-N 0.000 claims 1
- CXFIJOIUEFZMPL-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCN2CCOCC2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCN2CCOCC2)OC)NCCCCC CXFIJOIUEFZMPL-UHFFFAOYSA-N 0.000 claims 1
- GUQLIIRSXGTEOH-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCO)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CC(=O)OCCO)OC)NCCCCC GUQLIIRSXGTEOH-UHFFFAOYSA-N 0.000 claims 1
- IPOKHQKKYBVTRQ-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CCC(=O)OCC(=O)N2CCOCC2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(C=C2)CCC(=O)OCC(=O)N2CCOCC2)OC)NCCCCC IPOKHQKKYBVTRQ-UHFFFAOYSA-N 0.000 claims 1
- QVOMNIZXHGDOSF-VQHVLOKHSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)/C=C/C(=O)OCC(=O)N2CCOCC2)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)/C=C/C(=O)OCC(=O)N2CCOCC2)NCCCCC QVOMNIZXHGDOSF-VQHVLOKHSA-N 0.000 claims 1
- DWUQECPGRFUAPF-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)C(C(=O)OC)(F)F)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)C(C(=O)OC)(F)F)NCCCCC DWUQECPGRFUAPF-UHFFFAOYSA-N 0.000 claims 1
- XKTDCSNRVNSJCL-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)OC)NCCCCC XKTDCSNRVNSJCL-UHFFFAOYSA-N 0.000 claims 1
- AZSRICQTDGPXHM-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)OCC(=O)N2CCOCC2)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)OCC(=O)N2CCOCC2)NCCCCC AZSRICQTDGPXHM-UHFFFAOYSA-N 0.000 claims 1
- CGJMKTBLNLYJHB-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)OCC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)OCC)NCCCCC CGJMKTBLNLYJHB-UHFFFAOYSA-N 0.000 claims 1
- JLVGGBGDDHERCL-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)OCCN(C)C)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)OCCN(C)C)C=CC2OC)NCCCCC JLVGGBGDDHERCL-UHFFFAOYSA-N 0.000 claims 1
- SVVQSCXECIIRGC-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)OCCN1CCN(CC1)C)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)OCCN1CCN(CC1)C)C=CC2OC)NCCCCC SVVQSCXECIIRGC-UHFFFAOYSA-N 0.000 claims 1
- DTXPCGHJNKAOON-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)OCCN1CCNCC1)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(OCC(=O)OCCN1CCNCC1)C=CC2OC)NCCCCC DTXPCGHJNKAOON-UHFFFAOYSA-N 0.000 claims 1
- 208000007222 Physiological Sexual Dysfunction Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987314P | 2014-05-01 | 2014-05-01 | |
| US61/987,314 | 2014-05-01 | ||
| PCT/US2015/028285 WO2015168279A1 (en) | 2014-05-01 | 2015-04-29 | Compounds and compositions as toll-like receptor 7 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514839A JP2017514839A (ja) | 2017-06-08 |
| JP2017514839A5 true JP2017514839A5 (OSRAM) | 2018-06-14 |
| JP6541689B2 JP6541689B2 (ja) | 2019-07-10 |
Family
ID=53264739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565403A Expired - Fee Related JP6541689B2 (ja) | 2014-05-01 | 2015-04-29 | Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9944649B2 (OSRAM) |
| EP (1) | EP3137468B1 (OSRAM) |
| JP (1) | JP6541689B2 (OSRAM) |
| KR (1) | KR20160144399A (OSRAM) |
| CN (1) | CN106459058B (OSRAM) |
| AU (1) | AU2015253225B2 (OSRAM) |
| BR (1) | BR112016025048A2 (OSRAM) |
| CA (1) | CA2945504A1 (OSRAM) |
| EA (1) | EA032487B1 (OSRAM) |
| ES (1) | ES2908150T3 (OSRAM) |
| IL (1) | IL248311B (OSRAM) |
| MX (1) | MX380777B (OSRAM) |
| NZ (1) | NZ724878A (OSRAM) |
| SG (1) | SG11201608299TA (OSRAM) |
| WO (1) | WO2015168279A1 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Związki i kompozycje jako agonisty receptora toll-like 7 |
| PL3190113T3 (pl) | 2014-08-15 | 2021-10-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Związki pirolopirymidynowe stosowane jako agonista TLR7 |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| MA44334A (fr) * | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| EP4257198A3 (en) | 2017-08-22 | 2023-10-18 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof |
| EP3690030A4 (en) | 2017-09-28 | 2021-06-23 | Industry-Academic Cooperation Foundation, Yonsei University | PROCESS FOR THE PRODUCTION OF SUPPRESSIVE CELLS OF MYELOID ORIGIN, SUPPRESSIVE CELLS OF MYELOID ORIGIN THUS PRODUCED AND THEIR USES |
| EP3710059A1 (en) | 2017-11-14 | 2020-09-23 | Dynavax Technologies Corporation | Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| WO2020089811A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| EP3914263A4 (en) * | 2019-01-22 | 2022-09-21 | Tufts Medical Center, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES AND DISORDERS |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CN114269749B (zh) * | 2019-06-10 | 2024-10-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| CN114206392A (zh) * | 2019-06-10 | 2022-03-18 | 苏特罗生物制药公司 | 免疫调节剂抗体药物偶联物及其用途 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097106A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| CN115151548A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20230122249A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US20230131192A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP2023512208A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| KR20220132590A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| US20230127326A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN113476600B (zh) * | 2021-07-09 | 2023-05-30 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
| WO2024095964A1 (ja) | 2022-10-31 | 2024-05-10 | アステラス製薬株式会社 | Ｔｏｌｌ様受容体７／８デュアルアゴニスト化合物を含む抗体薬物複合体 |
| KR20250128394A (ko) | 2022-11-30 | 2025-08-27 | 리제너론 파마슈티칼스 인코포레이티드 | Tlr7 작용제 및 이의 항체-약물-접합체 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE147386T1 (de) * | 1991-08-12 | 1997-01-15 | Takeda Chemical Industries Ltd | Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel |
| WO1995033752A1 (en) | 1994-06-09 | 1995-12-14 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| AU4591600A (en) | 1999-05-05 | 2000-11-21 | Aventis Pharma Limited | Substituted bicyclic compounds |
| PL1713806T3 (pl) | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| CN1993362B (zh) * | 2004-06-02 | 2010-12-15 | 武田药品工业株式会社 | 稠合的杂环化合物 |
| RU2389731C2 (ru) | 2004-06-02 | 2010-05-20 | Такеда Фармасьютикал Компани Лимитед | Конденсированное гетероциклическое соединение |
| BRPI0608513A2 (pt) | 2005-03-15 | 2010-01-05 | Irm Llc | compostos e composições como inibidores da proteìna quinase |
| EP1939201A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CN101981036B (zh) | 2008-02-06 | 2013-09-04 | 诺瓦提斯公司 | 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途 |
| WO2010036928A1 (en) * | 2008-09-26 | 2010-04-01 | Takeda Pharmaceutical Company Limited | Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation) |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| EP2396328A2 (en) * | 2009-02-11 | 2011-12-21 | The Regents of The University of California | Toll-like receptor modulators and treatment of diseases |
| WO2010117936A1 (en) | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| US20130137709A1 (en) | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| CA2803056C (en) | 2010-06-23 | 2017-05-16 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| MX365114B (es) * | 2012-10-10 | 2019-05-23 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. |
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Związki i kompozycje jako agonisty receptora toll-like 7 |
-
2015
- 2015-04-29 ES ES15724409T patent/ES2908150T3/es active Active
- 2015-04-29 KR KR1020167030102A patent/KR20160144399A/ko not_active Ceased
- 2015-04-29 CA CA2945504A patent/CA2945504A1/en not_active Abandoned
- 2015-04-29 SG SG11201608299TA patent/SG11201608299TA/en unknown
- 2015-04-29 WO PCT/US2015/028285 patent/WO2015168279A1/en not_active Ceased
- 2015-04-29 EA EA201692201A patent/EA032487B1/ru not_active IP Right Cessation
- 2015-04-29 CN CN201580021681.2A patent/CN106459058B/zh not_active Expired - Fee Related
- 2015-04-29 EP EP15724409.6A patent/EP3137468B1/en active Active
- 2015-04-29 AU AU2015253225A patent/AU2015253225B2/en not_active Ceased
- 2015-04-29 BR BR112016025048A patent/BR112016025048A2/pt not_active IP Right Cessation
- 2015-04-29 MX MX2016014308A patent/MX380777B/es unknown
- 2015-04-29 JP JP2016565403A patent/JP6541689B2/ja not_active Expired - Fee Related
- 2015-04-29 NZ NZ724878A patent/NZ724878A/en not_active IP Right Cessation
- 2015-04-29 US US15/307,510 patent/US9944649B2/en active Active
-
2016
- 2016-10-11 IL IL248311A patent/IL248311B/en active IP Right Grant
-
2018
- 2018-02-27 US US15/906,424 patent/US10407431B2/en active Active
-
2019
- 2019-07-24 US US16/521,211 patent/US10844068B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514839A5 (OSRAM) | ||
| JP2017514838A5 (OSRAM) | ||
| JP2017504635A5 (OSRAM) | ||
| JP2019513804A5 (OSRAM) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2017528503A5 (OSRAM) | ||
| JP2017504576A5 (OSRAM) | ||
| JP2015524412A5 (OSRAM) | ||
| JP2017527578A5 (OSRAM) | ||
| JP2018537535A5 (OSRAM) | ||
| JP2016516020A5 (OSRAM) | ||
| JP2014523901A5 (OSRAM) | ||
| JP2016056183A5 (OSRAM) | ||
| JP2020506171A5 (OSRAM) | ||
| RU2016134751A (ru) | Соединения | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2017537940A5 (OSRAM) | ||
| JP2014521625A5 (OSRAM) | ||
| JP2017523225A5 (OSRAM) | ||
| JP2018529770A5 (OSRAM) | ||
| JP2011500621A5 (OSRAM) | ||
| JP2014525426A5 (OSRAM) | ||
| JP2012523440A5 (OSRAM) | ||
| RU2018112993A (ru) | Соединения и способы для ингибирования JAK | |
| JP2007522142A5 (OSRAM) |